351 related articles for article (PubMed ID: 18695083)
1. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
Saini SD; Fendrick AM; Scheiman JM
Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
[TBL] [Abstract][Full Text] [Related]
3. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.
Takabayashi N; Murata K; Tanaka S; Kawakami K
Pharmacoeconomics; 2015 Oct; 33(10):1091-100. PubMed ID: 25995130
[TBL] [Abstract][Full Text] [Related]
6. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
de Groot NL; van Haalen HG; Spiegel BM; Laine L; Lanas A; Focks JJ; Siersema PD; van Oijen MG
Cardiovasc Drugs Ther; 2013 Aug; 27(4):341-57. PubMed ID: 23417566
[TBL] [Abstract][Full Text] [Related]
7. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding.
Tsoi KK; Lau JY; Sung JJ
Gastrointest Endosc; 2008 Jun; 67(7):1056-63. PubMed ID: 18407271
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
[TBL] [Abstract][Full Text] [Related]
10. Single antiplatelet therapy for patients with previous gastrointestinal bleeds.
Gellatly RM; Ackman ML
Ann Pharmacother; 2008 Jun; 42(6):836-40. PubMed ID: 18413689
[TBL] [Abstract][Full Text] [Related]
11. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
13. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Schleinitz MD; Weiss JP; Owens DK
Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
[TBL] [Abstract][Full Text] [Related]
15. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy.
Ng FH; Lam KF; Wong SY; Chang CM; Lau YK; Yuen WC; Chu WM; Wong BC
Digestion; 2008; 77(3-4):173-7. PubMed ID: 18577887
[TBL] [Abstract][Full Text] [Related]
16. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
17. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
18. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.
Karnon J; Bakhai A; Brennan A; Pandor A; Flather M; Warren E; Gray D; Akehurst R
Int J Cardiol; 2006 May; 109(3):307-16. PubMed ID: 16026869
[TBL] [Abstract][Full Text] [Related]
19. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
Shaker M; Lobb A; Jenkins P; O'Rourke D; Takemoto SK; Sheth S; Burroughs T; Dykewicz MS
J Allergy Clin Immunol; 2008 Jan; 121(1):81-7. PubMed ID: 17716716
[TBL] [Abstract][Full Text] [Related]
20. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
